2025-08-14 - Analysis Report
Okay, here's the analysis based on the provided data, formatted as requested.

## RXRX (Recursion Pharmaceuticals Inc) Analysis

**Company Overview:** Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company leveraging AI to discover and develop novel therapeutics.

**1. Performance vs. S&P 500 (VOO)**

*   **Cumulative Return (RXRX):** -44.98%
*   **Cumulative Return (VOO):** 41.99%
*   **Divergence:** -86.0 (Max: 33.2, Min: -90.5, Relative Divergence: 3.6)

**Analysis:** RXRX has significantly underperformed the S&P 500.  The cumulative return divergence is substantial. The Relative Divergence of 3.6 suggests that this level of underperformance is near the bottom of its historical range relative to the S&P 500.

**Alpha, Beta Analysis**

| Year       | CAGR   | MDD    | Alpha    | Beta | Cap(B) |
|------------|--------|--------|----------|------|--------|
| 2021-2023  | 5.0%   | 73.6%  | -4.0%    | 0.0  | 4.3    |
| 2022-2024  | 0.0%   | 73.6%  | -26.0%   | 0.0  | 2.9    |
| 2023-2025  | 7.0%   | 73.6%  | -45.0%   | 0.0  | 2.5    |

**Analysis:**

*   **CAGR:** The Compound Annual Growth Rate (CAGR) shows fluctuating performance over different periods. The most recent period (2023-2025) shows a CAGR of 7.0%.
*   **MDD:** The Maximum Drawdown (MDD) remains consistently high at 73.6% across all periods, indicating significant risk and volatility.
*   **Alpha:** The negative Alpha values indicate that RXRX has underperformed relative to its benchmark (S&P 500) during all periods. The Alpha has become increasingly negative in more recent periods.
*   **Beta:** A Beta of 0.0 suggests that RXRX's returns are not correlated with the S&P 500's movements.
*   **Cap(B):** The market capitalization has decreased from $4.3B in 2021-2023 to $2.5B in 2023-2025, which is a substantial drop in market value.

**2. Recent Stock Price Movement**

*   **Current Price:** $5.70
*   **Last Market Data:**  Price: $5.70, Previous Close: $5.41, Change: 5.36%
*   **5-day Moving Average:** $5.43
*   **20-day Moving Average:** $5.86
*   **60-day Moving Average:** $5.26

**Analysis:**

The stock price is above the 5-day and 60-day moving averages but below the 20-day moving average. The recent 5.36% increase suggests a short-term upward price movement. The fact that  `{'price': 5.7, 'previousClose': 5.41, 'change': 5.36}` shows a notable increase indicates a potential rebound or reaction to recent news.

**3. Technical Indicators**

*   **Market Risk Indicator (MRI):** 0.32 (Low Risk)
*   **RSI:** 38.14
*   **PPO:** -1.40
*   **Hybrid Signal:** cash_70%_Sell 70.0% of holdings (3431 shares - Caution - MRI:0.34)
*   **Change in Relative Divergence (20-day):** -4.4 (Negative - Short-term decline)
*   **Expected Return:** -786.3%

**Analysis:**

*   The Low Risk MRI contrasts sharply with the extremely negative Expected Return.
*   RSI of 38.14 is approaching oversold territory.
*   The negative PPO suggests a bearish trend.
*   The Hybrid Signal indicates a cautious approach, suggesting selling a significant portion of holdings and increasing the cash position.
*   The negative change in relative divergence confirms recent underperformance relative to the S&P 500.
*   The expected return of -786.3% is exceptionally negative, suggesting very poor long-term prospects *relative to the S&P 500* based on the model's calculations. This should be taken with caution, as such extreme values can indicate issues with the model or unusual circumstances.

**4. Recent News & Significant Events**

*   **[2025-08-11]:**  Major business developments, regulatory changes, or market events.
*   **[2025-08-13]:** Analyst discussions on performance and outlook in the context of industry trends and global economic factors.
*   **[2025-08-10]:** Notable stock volatility, influenced by recent news, earnings reports, or executive actions.
*   **[2025-08-14]:**  Market experts highlighting risks and opportunities, advising monitoring of news and announcements.

**Analysis:** The news highlights recent volatility and scrutiny surrounding RXRX. The need for investors to monitor news and company announcements suggests uncertainty.

**5. Recent Earnings Analysis**

| 날짜       | EPS   | 매출      |
|------------|-------|-----------|
| 2025-08-05 | -0.41 | 0.02 B$   |
| 2025-05-05 | -0.5  | 0.01 B$   |
| 2024-11-06 | -0.34 | 0.03 B$   |
| 2024-08-08 | -0.4  | 0.01 B$   |
| 2025-08-05 | -0.4  | 0.01 B$   |

**Analysis:**

*   The company is consistently reporting negative EPS, indicating a lack of profitability.
*   Revenue has fluctuated, but remains relatively low.
*   The recent EPS and revenue figures suggest continued challenges.

**6. Financial Information**

**Revenue and Profitability**

| Quarter      | Revenue | Profit Margin |
|--------------|---------|---------------|
| 2025-06-30   | $0.02B  | -5.54%         |
| 2025-03-31   | $0.01B  | -47.31%         |
| 2024-12-31   | $0.00B  | -183.62%       |
| 2024-09-30   | $0.03B  | 53.69%         |
| 2024-06-30   | $0.01B  | 36.14%         |

**Capital and Profitability**

| Quarter      | Equity  | ROE      |
|--------------|---------|----------|
| 2025-06-30   | $0.92B  | -18.70%  |
| 2025-03-31   | $0.93B  | -21.68%  |
| 2024-12-31   | $1.03B  | -17.29%  |
| 2024-09-30   | $0.52B  | -18.27%  |
| 2024-06-30   | $0.58B  | -16.69%  |

**Analysis:**

*   **Revenue:** Revenue has been inconsistent, with a significant drop in one quarter.
*   **Profit Margin:** The profit margins are highly volatile, with significant losses in some quarters and profits in others. Recent quarters show a return to negative territory.
*   **Equity:** Equity decreased slightly during the last few quarters.
*   **ROE:** Return on Equity (ROE) is consistently negative, reinforcing the lack of profitability.

**7. Overall Summary**

RXRX is currently facing significant challenges. The stock has drastically underperformed the S&P 500, reflected in the large negative divergence and negative Alpha.  While the MRI suggests low market risk, the technical indicators (negative PPO, Hybrid Signal) and extremely negative Expected Return paint a concerning picture. Recent news points to volatility and uncertainty.  The company is consistently reporting negative EPS and inconsistent revenue, resulting in negative ROE.  Although there are some positive profit margins in the past, the financial results are not encouraging, so further monitoring is warranted.
